CoronaVac vaccine does not affect ovarian reserve.

Area of Science:

• Reproductive Endocrinology
• Vaccinology
• Infectious Diseases

Background:

• COVID-19 infection is linked to negative effects on female fertility and potential ovarian damage.
• Understanding the impact of vaccines on reproductive health is crucial for women of reproductive age.
• Previous research indicates a need to assess vaccine safety concerning ovarian reserve.

Purpose of the Study:

• To investigate the effect of the CoronaVac vaccine on ovarian reserve in infertile female patients.
• To compare key fertility markers before and after COVID-19 vaccination.
• To provide evidence regarding the safety of CoronaVac for female reproductive health.

Main Methods:

• Retrospective study design involving 46 infertile female patients.
• Patients received two doses of CoronaVac vaccine one month apart.
• Comparison of Anti-Müllerian Hormone (AMH) levels and folliculometry data before vaccination and one month post-vaccination.

Main Results:

• No statistically significant difference was observed in AMH levels before and after CoronaVac vaccination (p = 0.366).
• Follicle count also showed no significant change following vaccination (p = 0.610).
• The findings indicate that CoronaVac does not negatively affect ovarian reserve markers.

Conclusions:

• CoronaVac vaccination appears to be a safe and rational strategy to protect ovarian reserve in women.
• The study supports the use of COVID-19 vaccination in women of reproductive age, particularly those facing infertility.
• Confirming vaccine safety can encourage wider vaccine uptake among women concerned about fertility.